These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32988659)

  • 1. Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    Papatheodoridis G; Sypsa V; Lampertico P
    J Hepatol; 2021 Jan; 74(1):246-247. PubMed ID: 32988659
    [No Abstract]   [Full Text] [Related]  

  • 2. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Wen Z; Feng Y; Yan X
    J Hepatol; 2021 Jan; 74(1):245-246. PubMed ID: 33008623
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.
    Pol S; Luzivika Nzinga C; Fontaine H; Carrat F;
    Aliment Pharmacol Ther; 2021 Mar; 53(5):659. PubMed ID: 33566398
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
    Lee HA; Seo YS; Kim SU
    Gastroenterology; 2020 Jun; 158(8):2310-2311. PubMed ID: 32201178
    [No Abstract]   [Full Text] [Related]  

  • 5. Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?
    Kamal F; Khan MA
    Gastroenterology; 2020 Jun; 158(8):2311-2312. PubMed ID: 32201182
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.
    Lampertico P; Papatheodoridis GV
    Aliment Pharmacol Ther; 2021 Mar; 53(5):657-658. PubMed ID: 33566425
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B.
    Choi WM; Choi J; Wong GL; Han S; Lim YS
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):87. PubMed ID: 33444532
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
    Tseng CH; Hsu YC; Chen TH; Ji F; Chen IS; Tsai YN; Hai H; Thuy LTT; Hosaka T; Sezaki H; Borghi JA; Cheung R; Enomoto M; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1039-1052. PubMed ID: 33007228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
    Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
    Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
    Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Bahadır Ö; Özdil K; Doğanay HL
    J Viral Hepat; 2021 May; 28(5):826-836. PubMed ID: 33586270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
    Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
    van Erpecum KJ; Sonneveld MJ
    Eur J Intern Med; 2021 Jul; 89():27-29. PubMed ID: 34023149
    [No Abstract]   [Full Text] [Related]  

  • 13. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.
    Pol S;
    Aliment Pharmacol Ther; 2021 Mar; 53(5):616-629. PubMed ID: 33464621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
    Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
    Pol S; Lusivika Nzinga C; Carrat F
    Aliment Pharmacol Ther; 2021 May; 53(9):1050. PubMed ID: 33831235
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.
    Ha Y; Chon YE; Kim MN; Lee JH; Hwang SG
    Sci Rep; 2020 Aug; 10(1):13537. PubMed ID: 32782369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Lee SW; Kwon JH; Lee HL; Yoo SH; Nam HC; Sung PS; Nam SW; Bae SH; Choi JY; Yoon SK; Han NI; Jang JW
    Gut; 2020 Jul; 69(7):1301-1308. PubMed ID: 31672838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
    Kamal F; Khan MA; Ahmed A; Nair S
    Gut; 2020 Nov; 69(11):2054-2056. PubMed ID: 32041745
    [No Abstract]   [Full Text] [Related]  

  • 19. No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir.
    Oh H; Yoon EL; Jun DW; Ahn SB; Lee HY; Jeong JY; Kim HS; Jeong SW; Kim SE; Shim JJ; Sohn JH; Cho YK;
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2793-2802.e6. PubMed ID: 32135246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients.
    Wang JG; Chen R; Wang LC
    Aliment Pharmacol Ther; 2021 May; 53(9):1048-1049. PubMed ID: 33831238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.